Welcome to Peptide Card of AntiTbPdb

This page displays user query in tabular form.

RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP details

Primary information
ID	antitb_1123,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv (ATCC 25618)
Cell Line	50 mg/L causes 80% growth inhibition of m. tuberculosis H37Rv
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1124,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv (ATCC 25618)
Cell Line	MIC50 = 17 Â± 9 mg/L
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1125,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv (ATCC 25618)
Cell Line	6.25 mg/L causes 30% growth inhibition of M. tuberculosis H37Rv
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1126,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain
Cell Line	50 mg/L causes 39 % growth inhibition
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1127,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain
Cell Line	MIC50 = 93 Â± 12 mg/L
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1128,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis P34/95 MDR (isoniazid and rifampicin) strain
Cell Line	50 mg/L causes 49 % growth inhibition
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1129,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis #894-D11 streptomycin resistant strain
Cell Line	50 mg/L causes 80% growth inhibition
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1130,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	BTB 98-492 drug suspectible swedish clinical isolate
Cell Line	50 mg/L causes 80% growth inhibition
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1131,
Name	11328767
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Amidation
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Amphipathic
Species	Natural
Strain	Isolated from porcine leucocytes
Inhibition Concentration	Mycobacterium smegmatis
In Vitro/ In vivo	Mycobacterium smegmatis (ATCC 19420)
Cell Line	IC90 = 50mg/L
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1516,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	Reduction in growth is inhibited to to 30 % at conc. 6.25 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1517,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	Reduction in growth is inhibited to to80% at conc. 50 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1518,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	IC50 = 17Â± 9 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1519,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis E1380/94 (MDR resistant stain)
Cell Line	IC50= 93Â± 12 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1520,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium smegmatis
In Vitro/ In vivo	Mycobacterium smegmatis susceptible strain
Cell Line	50 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1521,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	IC50= 50 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1522,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis E1380/94 (MDR resistant stain)
Cell Line	IC50= 50 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1523,
Name	25681127
N-Terminal modification	PR-39
C-Terminal Modification	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
Chemical Modification	Free
Linear/Cyclic	Free
Length	None
Chirality	Linear
Nature	39
Source	L
Origin	Cationic
Species	Natural
Strain	Derived from pig porcine
Inhibition Concentration	Mycobacterium avium
In Vitro/ In vivo	Mycobacterium avium susceptible strain
Cell Line	MIC= 50 mg/L
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),